国产日产欧美精品-亚洲国产综合久久精品-色综合色国产热无码一-亚洲欧美日本国产,免费观看一区二区三区_在线观看片A免费不卡观看_亚洲а∨天堂久久精品_99久无码中文字幕一本久道

產(chǎn)品展廳收藏該商鋪

您好 登錄 注冊(cè)

當(dāng)前位置:
美國(guó)布魯克海文儀器公司>技術(shù)文章>Nanobrook Omni測(cè)量應(yīng)用案例-32

技術(shù)文章

Nanobrook Omni測(cè)量應(yīng)用案例-32

閱讀:323          發(fā)布時(shí)間:2018-8-13
 文獻(xiàn)名:Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer 

 

作者:Tanaya Vaidya1, Robert M. Straubinger2, Sihem Ait-Oudhia1 

    1.Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy University of Florida, Orlando, USA

    2.Department of Pharmaceutical Sciences University at Buffalo, State University of New York, Buffalo, USA

 

摘要:

Purpose

Trastuzumab combined with Doxorubicin (DOX) demonstrates significant clinical activity in human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC). However, emergence of treatment resistance and trastuzumab associated cardiotoxicity remain clinical challenges. In an effort to improve patient outcome, we have developed and evaluated novel tri-functional immunoliposomes (TFIL) that target HER2-receptors on BC cells and CD3-receptors on T-lymphocytes, and deliver DOX.

 

Methods

Trastuzumab (anti-HER2) and OKT-3 (anti-CD3) antibodies were conjugated to liposomes using a micelle-transfer method. Cytotoxicity of targeted immunoliposomes loaded with DOX was examined in vitro on HER2-positive BC cells (BT474), with peripheral blood monocytic cells (PBMC) as immune effector cells.

 

Results

TFIL demonstrated high antibody-liposome conjugation ratios (100130 μg protein/μmol phospholipid) and cargo capacity (0.21 mol:mol drug:lipid), highly efficient DOX loading (>90%), a particle size favorable for extended circulation (~150 nm), and good stability (up to 3 months at 4°C). In the presence of PBMCs, TFIL showed complete killing of BT474 cells, and were superior to mono-targeted trastuzumab-bearing liposomes, non-targeted liposomes, and free Trastuzumab and DOX.

 

Conclusions

Novel anti-HER2xCD3+DOX TFIL show promise as a means to both engage immune cells against HER2 positive breast cancer cells and deliver chemotherapy, and have the potential to improve clinical outcomes.

收藏該商鋪

請(qǐng) 登錄 后再收藏

提示

您的留言已提交成功!我們將在第一時(shí)間回復(fù)您~

對(duì)比框

產(chǎn)品對(duì)比 產(chǎn)品對(duì)比 聯(lián)系電話 二維碼 意見(jiàn)反饋 在線交流

掃一掃訪問(wèn)手機(jī)商鋪
010-62081908
在線留言
肥城市| 雷山县| 南汇区| 板桥市| 和顺县| 从江县| 贞丰县| 于都县| 万州区| 西和县| 青龙| 宝应县| 雅江县| 黄石市| 宁阳县| 嵩明县| 布尔津县| 乐都县| 察雅县| 远安县| 乌拉特中旗| 隆昌县| 波密县| 敖汉旗| 安泽县| 阿拉善右旗| 莲花县| 呼和浩特市| 拉孜县| 武夷山市| 定州市| 连云港市| 东光县| 阜阳市| 固镇县| 长阳| 通渭县| 政和县| 和林格尔县| 杂多县| 华宁县|